International Association for the Study of Lung Cancer: Zongertinib Demonstrates Promising Efficacy in Patients With HER2-Mutant NSCLC - Primary Phase Ib Analysis of Beamion LUNG-1
September 10, 2024
September 10, 2024
AURORA, Colorado, Sept. 10 (TNSres) -- The International Association for the Study of Lung Cancer issued the following news release:
[San Diego, Calif.--September 9, 2024 10:05 a.m.) -- The HER2-specific tyrosine kinase inhibitor zongertinib was well tolerated and demonstrated promising efficacy in patients with HER2 mutation-positive non-small cell lung cancer, meeting the primary endpoint of the Beamion LUNG-1 Phase Ib Cohort 1 study, according to research presented today at the I . . .
[San Diego, Calif.--September 9, 2024 10:05 a.m.) -- The HER2-specific tyrosine kinase inhibitor zongertinib was well tolerated and demonstrated promising efficacy in patients with HER2 mutation-positive non-small cell lung cancer, meeting the primary endpoint of the Beamion LUNG-1 Phase Ib Cohort 1 study, according to research presented today at the I . . .